Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Breast Cancer × abemaciclib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 52 Neoplasm Metastasis 16 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 6 Brain Neoplasms 5 Prostatic Neoplasms 3 Melanoma 3 Glioma 3 Colorectal Neoplasms 3 Sarcoma, Ewing 2 Recurrence 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma 2 Glioblastoma 2 Endometrial Neoplasms 2 Breast Diseases 2 Advanced Cancer 2 Urogenital Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Spinal Cord Neoplasms 1 Solid Tumor, Adult 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Osteosarcoma 1

Interventions

Fulvestrant 13 Letrozole 6 Anastrozole 5 palbociclib 4 exemestane 3 Docetaxel 3 Paclitaxel 2 Injections 2 Dasatinib 2 Capecitabine 2 Alpelisib 2 AZD9833 2 vandetanib 1 ribociclib 1 irinotecan sucrosofate 1 entinostat 1 elacestrant 1 cediranib 1 abemaciclib 1 XMT-1522 1 Vinorelbine 1 Sirolimus 1 Ritonavir 1 Itraconazole 1 Immunotherapy, Adoptive 1 Goserelin 1 Everolimus 1 Decitabine 1 Combined Modality Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06380751 2026-04-14

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡